All Blog Posts

Topics
Natural Killer Cells in Brain Tumor Research
The use of Natural Killer (NK) cells, in treating human cancers, specifically brain cancers, has recently seen significant progress. NK cell therapies, in combination with other immunotherapies or treatments, hold promise for enhancing the body's natural defenses against brain tumors. Read our blog to learn why.
-
Topics
CD markers in human diseases: an informative guide
Explore the role of primary antibodies targeting CD proteins in neurobiology and cancer research. Read more to discover how these antibodies facilitate precise cell population identification in the nervous system and contribute to human cancer disease diagnosis and prognosis. -
Topics
Research Highlights: protein markers in Glioma Research
Explore the importance of new biomarkers in glioma research and their potential to revolutionize diagnosis, prognosis, and treatment of this aggressive brain tumor. Discover new emerging biomarkers that will help to enhance patient outcomes and guide personalized therapeutic strategies. -
Topics
Reporting from the BNA23 Neuroscience Conference
The British Neuroscience Association (BNA) hosted its 6th International Festival of Neuroscience in April. Atlas Antibodies was there promoting his catalog of primary antibodies for Neuroscience research. Were you also there? Here we briefly summarise the exciting lectures we attended this year. -
7 Types of Biomarkers
Biomarkers are measurable biological indicators with numerous clinical applications each providing unique information about an individual's health status. The identification and development of new biomarkers can greatly improve disease detection, prognosis, and treatment. There are seven categories of clinical applications of biomarkers, each with a unique purpose and significance. Learn more! -
How Neural Lineage Cells Contribute to Brain Function and Behavior
Understanding the development and progression of lineage cell types within the nervous system is critical for understanding the mechanisms of neurodegeneration and other brain diseases and can help identify potential sites for intervention. Read more and explore our primary antibodies targeting relevant markers in the neural lineage development pathways. -
2022 Atlas Antibodies Blog Recap
Good stuff is worth sharing! 2022. In 12 blog posts, we have opened our doors to you with a multitude of ideas, interactions, and support flowing in. To our incredible community of customers and contributors, we say Thank You! -
Topics
New markers targeting neuroendocrine neoplasms NENs
A neuroendocrine neoplasm (NEN) begins in the cells of the neuroendocrine system. These cells have traits of both hormone-producing endocrine cells and nerve cells. The advent of second-generation NEN markers for use in immunohistochemistry has considerably expanded the pathology toolbox for diagnosing and classifying NENs. Atlas Antibodies has released new monoclonal markers targeting NENs. Read more in our new blog post! -
Topics
Employee Spotlight: Ava Zakizadeh
Meet Ava Zakizadeh, Lab Engineer at Atlas Antibodies. This year was full of success for her as she was awarded by colleagues and recently got promoted. Colleagues describe her as approachable, open to cross-functional collaboration, and helpful at any time, always going the extra mile. They also say that she always contributes to a caring and fun environment in teams and meetings. Find out more about her journey in this interview. -
Topics
FENS Forum 2022 with Atlas Antibodies
Chiara Musillo, a Ph.D. student from La Sapienza University of Rome, Italy, won the first Atlas Antibodies’ travel grant competition to attend the FENS Forum 2022 in Paris, held in July. Our scientists at Atlas Antibodies selected her research project among many good applications. Here is her story in her own words. -
My days at Atlas Antibodies
In the last three years, our company has given opportunities to Master’s students to join 20 weeks program and do their thesis. Since then, five students used that chance and after they finished the program, they were usually offered a job in Atlas Antibodies. Here is one of those stories.